0001209191-19-047178.txt : 20190822
0001209191-19-047178.hdr.sgml : 20190822
20190822192004
ACCESSION NUMBER: 0001209191-19-047178
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190821
FILED AS OF DATE: 20190822
DATE AS OF CHANGE: 20190822
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mahatme Sandesh
CENTRAL INDEX KEY: 0001511034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 191046901
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-08-21
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001511034
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
EVP, CFO & CBO
Common Stock
2019-08-21
4
M
0
100000
23.85
A
130179
D
Common Stock
2019-08-21
4
F
0
57465
101.50
D
72714
D
Common Stock
2019-08-22
5
G
0
E
42535
0.00
D
30179
D
Common Stock
12012
I
By trust
Stock Appreciation Right
23.85
2019-08-21
4
M
0
100000
0.00
D
2022-11-05
Common Stock
100000
0
D
This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes.
This transaction involved a gift of shares of common stock by the reporting person to a family trust.
25% of the shares subject to the SAR vested on the first anniversary measured from November 5, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vested in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the SAR were fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme
2019-08-22